COMMUNIQUÉS West-GlobeNewswire

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
12/03/2026
CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
12/03/2026
Award recognizes leading chronic kidney disease advocates WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and [...]
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
12/03/2026
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Year 2026 Guidance [...]
Aveanna Healthcare Holdings Announces Agreement to Acquire Family First Homecare
12/03/2026
ATLANTA, March 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today [...]
Amerita First in Nation to Earn ACHC Distinction in Immunoglobulin Therapy, Reflecting Company’s Commitment to High-Quality Infusion Care
12/03/2026
GREENWOOD VILLAGE, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Amerita, a leading national provider of specialty infusion services, is the first infusion pharmacy in the nation to earn the Distinction in Ig Therapy [...]
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
12/03/2026
Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industry Appointment supports Helus Pharma’s continued maturation as the company advances its [...]
InflaRx to Report Full Year 2025 Results on March 19, 2026
12/03/2026
JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
GUANGZHOU, China, March 12, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in [...]
Demande d’autorisation de mise sur le marché de TECVAYLI®▼ (teclistamab) en monothérapie soumise à l’EMA pour le myélome multiple en rechute ou réfractaire après au moins une ligne de traitement antérieure
12/03/2026
Application appuyée par des données de la Phase 3 renforçant les schémas thérapeutiques à base de teclistamab comme traitement standard potentiel après au moins une thérapie antérieure 1 La monothérapie par teclistamab [...]
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
12/03/2026
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
12/03/2026
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and [...]
Indivior Announces Proposed Convertible Senior Notes Offering
12/03/2026
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of [...]
ProQR Announces Year End 2025 Operating and Financial Results
12/03/2026
Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026 Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3) Ended 2025 with € 92. [...]
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
12/03/2026
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026 Seres [...]
Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance with “gesund leben” Cooperation and Alliance Healthcare Deutschland to Accelerate Market Expansion and Strengthen Pharmacy Access Across Germany
12/03/2026
DENSBORN, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), has announced a strategic partnership with Tilray Medical, CC Pharma, [...]
Vanqua Bio to Present at the AD/PD™ 2026 International Conference
12/03/2026
CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD TM 2026 International Conference on Alzheimer’s and Parkinson’s [...]
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
12/03/2026
Reports record fourth quarter 2025 total revenue of $11.3 million , representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million , representing 20% growth compared to [...]
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
12/03/2026
Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia, affecting millions [...]
Verano Announces Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Company delivers sequential revenue and margin improvement within guidance in the fourth quarter; closes 2025 with top three market share positions 1 across all competing categories Newly-announced $195 million credit [...]

Pages